Core B-Specimen and Reagent Core
核心 B 样本和试剂核心
基本信息
- 批准号:9141191
- 负责人:
- 金额:$ 24.34万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-15 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountabilityAcuteAntibodiesAntibody-mediated protectionAntigensArchivesBackBiologicalBiological AssayBiopsyCell LineCellsCommunitiesCore ProteinDataData QualityDatabasesEnsureFoundationsFundingGoalsGrantHIVHIV-1Macaca mulattaMonoclonal AntibodiesPassive ImmunizationPeptidesPeripheral Blood Mononuclear CellPlasmaPopulationPrimatesPrincipal InvestigatorProceduresProtein SubunitsProteinsQualifyingReagentResearchResearch PersonnelResourcesSamplingScheduleSourceSpecific qualifier valueSpecimenT-LymphocyteTestingVaccinatedWorkbaseenv Gene Productsprogramsquality assurancerectalsymposium
项目摘要
The principal significance of Core B is that it will provide a centralized source for the receipt, tracking, storage,
and distribution of valuable biological specimens generated by all three projects in addition to providing
standardized research reagents to the projects. This will be accomplished using established standard
operating procedures that are in place from our ongoing multi-project programs funded by grants from The Bill
and Melinda Gates Foundation. This strategy strengthens the quality of data across the projects and provides
a high-degree of accountability for quality assurance. In addition, Core B will archive both biological
specimens and test articles such as immunogens and mAbs used for passive immunization. These will be
used as needed by the three projects and they will be shared with the larger research community upon request
by other investigators. The three projects will have priority for receiving the specimens and test articles
required to accomplish their specific aims. The Principal Investigator and Project Leaders will determine
additional use of the specimens and test articles during regularly scheduled conference calls as specified in
Core A. In the case of acute need, the decision will be made by an ad hoc conference call. The same team
will establish priorities for external requests on an ad hoc basis for limited specimens or test articles. If the
request is not for a limited material, it will be honored pro forma. Core B will also work closely with Core A
where data will be archived to ensure that it can be readily tracked back to the specimens and test articles. The
goals of Core B will be achieved by two specific aims. Aim 1: Provide specimens from immunized and
challenged rhesus macaques. Aim 2: Provide antibody and protein reagents to the Program.
核心B的主要意义在于,它将为接收、跟踪、存储
和分发所有三个项目产生的有价值的生物标本,
标准化的研究试剂。这将使用已建立的标准来完成
我们正在进行的多项目计划中的操作程序,这些计划由该法案的拨款资助
梅琳达·盖茨基金会这一战略加强了各项目的数据质量,
对质量保证高度负责。此外,核心B将存档生物学
用于被动免疫的免疫原和mAb等标本和供试品。这些将是
三个项目根据需要使用,并将根据要求与更大的研究社区共享
其他调查员。这三个项目将优先接收标本和供试品
以实现其特定目标。主要研究者和项目负责人将确定
在定期安排的电话会议期间额外使用样本和供试品,如
核心A。在紧急需要的情况下,将通过特别电话会议作出决定。同一个团队
将为有限样本或供试品的外部请求建立临时优先级。如果
要求不是一个有限的材料,它将被兑现形式。核心B也将与核心A密切合作
数据将在此处存档,以确保其可随时追溯至样本和供试品。的
核心B的目标将通过两个具体目标实现。目标1:提供免疫和
挑战恒河猴。目的二:为项目提供抗体和蛋白质试剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WUYUAN LU其他文献
WUYUAN LU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WUYUAN LU', 18)}}的其他基金
D-peptide activators of p53 as anticancer therapeutics
p53 的 D 肽激活剂作为抗癌疗法
- 批准号:
8774207 - 财政年份:2013
- 资助金额:
$ 24.34万 - 项目类别:
D-peptide activators of p53 as anticancer therapeutics
p53 的 D 肽激活剂作为抗癌疗法
- 批准号:
8637246 - 财政年份:2013
- 资助金额:
$ 24.34万 - 项目类别:
High-throughput screening for HIV assembly and maturation inhibitors
HIV组装和成熟抑制剂的高通量筛选
- 批准号:
8545199 - 财政年份:2012
- 资助金额:
$ 24.34万 - 项目类别:
High-throughput screening for HIV assembly and maturation inhibitors
HIV组装和成熟抑制剂的高通量筛选
- 批准号:
8735972 - 财政年份:2012
- 资助金额:
$ 24.34万 - 项目类别:
High-throughput screening for HIV assembly and maturation inhibitors
HIV组装和成熟抑制剂的高通量筛选
- 批准号:
8262517 - 财政年份:2012
- 资助金额:
$ 24.34万 - 项目类别:
D-peptide inhibitors of HIV assembly and maturation
HIV 组装和成熟的 D 肽抑制剂
- 批准号:
8020942 - 财政年份:2010
- 资助金额:
$ 24.34万 - 项目类别:
Inhibition of Anthrax Lethal Factor by alpha-defensins
α-防御素对炭疽致死因子的抑制
- 批准号:
8134677 - 财政年份:2010
- 资助金额:
$ 24.34万 - 项目类别:
D-peptide inhibitors of HIV assembly and maturation
HIV 组装和成熟的 D 肽抑制剂
- 批准号:
7929943 - 财政年份:2010
- 资助金额:
$ 24.34万 - 项目类别:
相似海外基金
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
急性和持续性 Epstein-Barr 病毒感染中的中和抗体
- 批准号:
8965501 - 财政年份:2014
- 资助金额:
$ 24.34万 - 项目类别:
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
急性和持续性 Epstein-Barr 病毒感染中的中和抗体
- 批准号:
9182818 - 财政年份:2014
- 资助金额:
$ 24.34万 - 项目类别:
Neutralizing Antibodies in Acute and Persistent Epstein-Barr Virus Infection
急性和持续性 Epstein-Barr 病毒感染中的中和抗体
- 批准号:
8854409 - 财政年份:2014
- 资助金额:
$ 24.34万 - 项目类别:
Development ofTherapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells
针对人急性髓性白血病干细胞的治疗性抗体的开发
- 批准号:
G1000729/1 - 财政年份:2010
- 资助金额:
$ 24.34万 - 项目类别:
Research Grant
The relationship between anti-donor antibodies and acute rejection in lung transplantation
抗供体抗体与肺移植急性排斥反应的关系
- 批准号:
12671311 - 财政年份:2000
- 资助金额:
$ 24.34万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6347230 - 财政年份:2000
- 资助金额:
$ 24.34万 - 项目类别:
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6201348 - 财政年份:1999
- 资助金额:
$ 24.34万 - 项目类别:
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6100126 - 财政年份:1998
- 资助金额:
$ 24.34万 - 项目类别:
NON-NEUTRALIZING ANTIBODIES IN ACUTE PRIMARY HIV INFECTION
急性原发性 HIV 感染中的非中和抗体
- 批准号:
6235545 - 财政年份:1997
- 资助金额:
$ 24.34万 - 项目类别:
HUMAN AND MURINE HYBRIDOMA ANTIBODIES IN ACUTE LEUKEMIAS
急性白血病中的人和鼠杂交瘤抗体
- 批准号:
3172843 - 财政年份:1983
- 资助金额:
$ 24.34万 - 项目类别:














{{item.name}}会员




